日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

二甲双胍以一种不依赖于AMP激酶的方式抑制卵巢癌细胞的生长。

Rattan, R; Giri, S; Hartmann, L C; Shridhar, V

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

一项针对复发或持续性卵巢癌或原发性腹膜癌患者的自体造血干细胞移植联合递增剂量拓扑替康、环磷酰胺和卡铂的I期临床试验

Litzow, M R; Peethambaram, P P; Safgren, S L; Keeney, G L; Ansell, S M; Dispenzieri, A; Elliott, M A; Gastineau, D A; Gertz, M A; Inwards, D J; Lacy, M Q; Micallef, I N M; Porrata, L F; Lingle, W L; Hartmann, L C; Frost, M H; Barrette, B A; Long, H J; Suman, V J; Reid, J M; Ames, M M; Kaufmann, S H

Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis

孕激素受体变异与卵巢癌风险的关系仅限于浸润性子宫内膜样癌亚型:来自卵巢癌协会联盟汇总分析的结果

Pearce, C L; Wu, A H; Gayther, S A; Bale, A E; Beck, P A; Beesley, J; Chanock, S; Cramer, D W; DiCioccio, R; Edwards, R; Fredericksen, Z S; Garcia-Closas, M; Goode, E L; Green, A C; Hartmann, L C; Hogdall, E; Kjaer, S K; Lissowska, J; McGuire, V; Modugno, F; Moysich, K; Ness, R B; Ramus, S J; Risch, H A; Sellers, T A; Song, H; Stram, D O; Terry, K L; Webb, P M; Whiteman, D C; Whittemore, A S; Zheng, W; Pharoah, P D P; Chenevix-Trench, G; Pike, M C; Schildkraut, J; Berchuck, A

Single-cell nonphotochemical hole burning of ovarian surface epithelial carcinoma and normal cells.

卵巢表面上皮癌和正常细胞的单细胞非光化学烧孔

Walsh R J, Matsuzaki S, Reinot T, Hayes J M, Kalli K R, Hartmann L C, Small G J

Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development

人钙调蛋白样蛋白免疫反应性的丧失是乳腺癌发展早期事件。

Rogers, M S; Foley, M A; Crotty, T B; Hartmann, L C; Ingle, J N; Roche, P C; Strehler, E E